TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05833204

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic colporrhaphy with 0-caliber barbed absorbable suture
Description: After the total laparoscopic hysterectomy, the colporrhaphy will be performed using a 0-caliber barbed absorbable suture (V-Loc ™, Covidien, Medtronic)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic colporrhaphy with standard 0-caliber absorbable suture
Description: After the total laparoscopic hysterectomy, the colporrhaphy will be performed using a 0-caliber absorbable suture made of a coated braided thread (Vicryl; Ethicon Inc, Sommerville, NJ)
Study: NCT06270706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLN-101095
Description: PLN-101095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLN-101095
Description: PLN-101095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab
Study: NCT05374278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]RP-115 PET/MRI or PET/CT and MRI
Description: An I.V. bolus injection of up to 10 millicurie (mCi) \[18F\]RP-115 will be administered, followed by a PET/MRI scan or by a combination of PET/CT and MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]RP-115 PET/MRI or PET/CT and MRI
Description: An I.V. bolus injection of up to 10 millicurie (mCi) \[18F\]RP-115 will be administered, followed by a PET/MRI scan or by a combination of PET/CT and MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]RP-115 PET/MRI or PET/CT and MRI
Description: An I.V. bolus injection of up to 10 millicurie (mCi) \[18F\]RP-115 will be administered, followed by a PET/MRI scan or by a combination of PET/CT and MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]RP-115 PET/MRI or PET/CT and MRI
Description: An I.V. bolus injection of up to 10 millicurie (mCi) \[18F\]RP-115 will be administered, followed by a PET/MRI scan or by a combination of PET/CT and MRI
Study: NCT04738292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onapristone
Description: Onapristone is a type I antiprogestin which prevents the PgR from dimerizing and blocks ligand induced protein kinase-mediated phosphorylation of the PgR.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant binds, blocks and degrades the ER, completely inhibiting ER signaling.
Study: NCT06209918

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bioptron light therapy
Description: patient will be sitting on comfortable chair with the hand placed on an armrest in an extended and supinated position. Firstly, the skin over the wrist area will be exposed and cleaned by alcohol to achieve maximal penetration of light. Then, the bioptron device will be held perpendicular to the surface of the treated area, at a distance of 10 cm.

Intervention type: DEVICE
Group type: OTHER
Intervention: wrist brace
Description: will keep the wrist in a neutral position, not bent back or bent down too far
Study: NCT06094036

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Structured and personalized program of physical exercise
Description: In line with the most recent guidelines, exercise prescription will require the clear definition of modality, intensity, frequency, duration and progression of exercise, tailored on patient's clinical conditions and goals.~This intervention will be accompanied by a nutrition program aiming for proper dietary habits in terms of both quantity and quality.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Structured and personalized program of physical exercise
Description: In line with the most recent guidelines, exercise prescription will require the clear definition of modality, intensity, frequency, duration and progression of exercise, tailored on patient's clinical conditions and goals.~This intervention will be accompanied by a nutrition program aiming for proper dietary habits in terms of both quantity and quality.
Study: NCT05769712

Intervention type: DIAGNOSTIC_TEST
Intervention: Shear wave ultrasonic imaging
Description: Shear wave ultrasonic imaging technique was used to measure the superficial and deep shear wave velocity of supraspinatus tendon at 10mm (distal end) and 15mm (proximal end) from the attachment end of the greater tubercle of the humerus on the long axis section of supraspinatus tendon.

Intervention type: DIAGNOSTIC_TEST
Intervention: Shear wave ultrasonic imaging
Description: Shear wave ultrasonic imaging technique was used to measure the superficial and deep shear wave velocity of supraspinatus tendon at 10mm (distal end) and 15mm (proximal end) from the attachment end of the greater tubercle of the humerus on the long axis section of supraspinatus tendon.
Study: NCT05292092

Intervention type: DRUG
Intervention: Essential pro
Description: Patients in whom treatment with (Essential Pro) has been attempted
Study: NCT05382143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atosiban
Description: Pilot study
Study: NCT06400810

Intervention type: DEVICE
Intervention: Analog Devices Inc.
Description: Wearable wrist device that collects Photoplethysmography, accelerometer data among other parameters.
Study: NCT06237270

Intervention type: PROCEDURE
Intervention: Nerve transfer surgery for elbow flexion
Description: A functioning but less important nerve (e.g. spinal accessory nerve, phrenic nerve, fascicle of median nerve, or fascicle of ulnar nerve) was transferred to nerves innervating biceps or brachialis muscle to restore elbow flexion.

Intervention type: PROCEDURE
Intervention: Nerve transfer surgery for elbow flexion
Description: A functioning but less important nerve (e.g. spinal accessory nerve, phrenic nerve, fascicle of median nerve, or fascicle of ulnar nerve) was transferred to nerves innervating biceps or brachialis muscle to restore elbow flexion.
Study: NCT05505552

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin K
Description: 1 mg/day phylloquinone (vitamin K1)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule once daily
Study: NCT06285500

Intervention type: OTHER
Intervention: Patient-specific treatments
Description: Treatment will be decided specifically for the patient based on biomarker test results.

Intervention type: OTHER
Intervention: Patient-specific treatments
Description: Treatment will be decided specifically for the patient based on biomarker test results.

Intervention type: OTHER
Intervention: Patient-specific treatments
Description: Treatment will be decided specifically for the patient based on biomarker test results.
Study: NCT05184855

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberry
Description: Blueberry powder intake

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo powder intake
Study: NCT05267704

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Samsung Gear Virtual Reality Headset
Description: VR headset displaying preselected game during renal biopsy
Study: NCT05262374

Intervention type: PROCEDURE
Intervention: Procedure/Surgery: Laparoscopic
Description: Surgeon

Intervention type: PROCEDURE
Intervention: Robotic
Description: Versius system.
Study: NCT06079294

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FDG PET
Description: Brain FDG PET performed 3 months after treatment initiation
Study: NCT06517381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Online Warning Signs of Mental Illness Literacy Program
Description: Digital Online Warning Signs of Mental Illness Literacy Program is comprised of 30-minute pre-recorded video and question-and-answer sessions. The videos were followed by case studies, success stories, and interactive question-and-answer sessions
Study: NCT05453721

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indocyanine green fluorescence imaging method
Description: Using indocyanine green fluorescence imaging method to identify intersegmental plane in segmentectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified inflation-deflation method
Description: Using modified inflation-deflation method to identify intersegmental plane in segmentectomy
Study: NCT05550324

Intervention type: PROCEDURE
Intervention: Blood draw
Description: One time intravenous blood draw

Intervention type: PROCEDURE
Intervention: Blood draw
Description: One time intravenous blood draw

Intervention type: PROCEDURE
Intervention: Blood draw
Description: One time intravenous blood draw

Intervention type: PROCEDURE
Intervention: Blood draw
Description: One time intravenous blood draw
Study: NCT05385406

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HPV genotyping
Description: Genotyping will be obtained by the Xpert system which uses 5 color channels containing primers and probes for the detection of specific genotypes or pooled results as follows: i) HPV 16, ii) HPV 18/45 in pooled result, iii) HPV types 31, 33, 35 52, or 58, in pooled result, iv) HPV types 51 or 59, in pooled result, and v) HPV types 39, 56, 66 or 68 in pooled result.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Visual inspection after application of acetic acid
Description: After application of acetic acid and Lugol's iodine, the cervix will be assessed using simplified ABCD criteria (A= acetowhite lesion within the transformation zone, B = spontaneous bleeding or upon slight touch, C (optional) = Lugol-positive coloring of acetowhite lesions, D = diameter \> 5mm of acetowhite lesion).
Study: NCT05500937

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: UDCA
Description: UDCA vs. placebo together with statin in ASCVD patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UDCA
Description: UDCA vs. placebo together with statin in ASCVD patients
Study: NCT06551038

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary suicide prevention intervention
Description: Psychoeducation workshop

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Art-based control intervention
Description: Slam poetry workshop
Study: NCT05226429

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UNAIR Inactivated COVID-19 Vaccine
Description: UNAIR Inactivated Covid-19 Vaccine contains S protein of SARS-CoV-2 virus, Aluminium hydroxide gel, 10 mM L-Histidine buffer, 0.005% Tween Polysorbate 80, and 0.9% Sodium chloride. Vaccine will be prepared in vial (1 ml per vial). One vial will be used for one injection only. The vial should be shaken well before injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UNAIR Inactivated COVID-19 Vaccine
Description: UNAIR Inactivated Covid-19 Vaccine contains S protein of SARS-CoV-2 virus, Aluminium hydroxide gel, 10 mM L-Histidine buffer, 0.005% Tween Polysorbate 80, and 0.9% Sodium chloride. Vaccine will be prepared in vial (1 ml per vial). One vial will be used for one injection only. The vial should be shaken well before injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CoronaVac Biofarma COVID-19 Vaccine
Description: Control vaccine in this study is existing CoronaVac-BioFarma inactivated COVID-19 vaccine which has been used widely in Indonesia.
Study: NCT06307379

Intervention type: OTHER
Intervention: no intervention
Description: only observational

Intervention type: OTHER
Intervention: no intervention
Description: only observational

Intervention type: OTHER
Intervention: no intervention
Description: only observational

Intervention type: OTHER
Intervention: no intervention
Description: only observational
Study: NCT05426174

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA NA vaccine
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA NA vaccine
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA NA vaccine
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: High Dose Quadrivalent Influenza Vaccine
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
Study: NCT06305481

Intervention type: DEVICE
Group type: OTHER
Intervention: P200TE
Description: SLO and OCT imaging
Study: NCT04941989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0022562
Description: HTL0022562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0022562
Description: HTL0022562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT04556266

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR T-Cell Infusion
Description: Dose Level -1: 1 x 10\^4 cells/kg Dose Level 1: 1 x 10\^5 cells/kg Dose Level 2: 2 x 10\^5 cells/kg Dose Level 3: 4 x 10\^5 cells/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR T-Cell Infusion
Description: Dose Level -1: 1 x 10\^4 cells/kg Dose Level 1: 1 x 10\^5 cells/kg Dose Level 2: 2 x 10\^5 cells/kg Dose Level 3: 4 x 10\^5 cells/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR T-Cell Infusion
Description: Dose Level -1: 1 x 10\^4 cells/kg Dose Level 1: 1 x 10\^5 cells/kg Dose Level 2: 2 x 10\^5 cells/kg Dose Level 3: 4 x 10\^5 cells/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR T-Cell Infusion
Description: Dose Level -1: 1 x 10\^4 cells/kg Dose Level 1: 1 x 10\^5 cells/kg Dose Level 2: 2 x 10\^5 cells/kg Dose Level 3: 4 x 10\^5 cells/kg
Study: NCT06095687

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Meditation
Description: Five, 20-minute audio-recorded training sessions of mindfulness of breath and body meditation, practiced over consecutive days, delivered remotely via Qualtrics.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Hypnosis
Description: Five, 20-minute audio-recorded training sessions of clinical hypnosis with suggestions targeting pain management, practiced over consecutive days, delivered remotely via Qualtrics.
Study: NCT04660383

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inspiratory Muscle Training
Description: Patients will be submitted to three weekly IMT sessions in three different intensities for a period of twelve weeks, totaling 36 sessions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Patients will be submitted to three weekly IMT sessions in three different intensities for a period of twelve weeks, totaling 36 sessions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Patients will be submitted to three weekly IMT sessions in three different intensities for a period of twelve weeks, totaling 36 sessions.
Study: NCT06140134

Intervention type: PROCEDURE
Intervention: Liver Transplant
Description: Whole liver allotransplantation will be performed for patients on the liver transplant waiting list
Study: NCT05170113

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alpinia galanga formulation
Description: Alpinia galanga formulation capsule- 1 capsule daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Theacrine formulation
Description: Theacrine formulation capsule- 1 capsule daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine formulation
Description: Caffeine formulation capsule- I capsule daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule- 1 capsule daily
Study: NCT05018793

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous adipose derived mesenchymal stem cells
Description: cultured autologous adult adipose derived mesenchymal stem cells
Study: NCT05255822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INNA-051
Description: Liquid for intra-nasal administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INNA-051
Description: Liquid for intra-nasal administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid for intra-nasal administration
Study: NCT05072288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote activity program
Description: Participant will have to do exercise at home everyday (15min/day)
Study: NCT05716464

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle medicine intervention
Description: The lifestyle medicine intervention includes six weekly sessions (i.e., participants will receive the intervention once per week) that are related to the following topics: (a) lifestyle psychoeducation, (b) physical activity, (c) dietary recommendation, (d) stress management, (e) sleep management and (f) motivation and goal-setting techniques. Each topic will be delivered during each face-to-face session and the duration of each session will be around 120 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for depression (CBT-D)
Description: The group-based CBT-D therapy includes six weekly sessions (i.e., participants will attend one 120-minute, face-to-face group therapy per week, and will be asked to practice taught-skills every day, for 42 days) that are related to the following topics: (a) psychoeducation, (b) cognitive restructuring, (c) behavioral activation, (d) self-care and relapse prevention.
Study: NCT05785169

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRAncenDS
Description: The HP+ curriculum includes total-site training and co-facilitation via participatory modules. To transform clinic culture, a multi-level approach that includes the whole facility and reaches all parties is required. The intervention aims to modify top-down mechanisms of influence. TRAnscenDS is modeled on these principles and supports the development of multiple SRD-reduction strategies (instituting comprehensive anti-racist and Diversity, Equity and Inclusion policies, monitoring and feedback systems; workforce equity), at the top two levels of the socioecological model (organizational/policy and systems/providers/staff), to in turn impact individual-level out-comes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRAncenDS
Description: The HP+ curriculum includes total-site training and co-facilitation via participatory modules. To transform clinic culture, a multi-level approach that includes the whole facility and reaches all parties is required. The intervention aims to modify top-down mechanisms of influence. TRAnscenDS is modeled on these principles and supports the development of multiple SRD-reduction strategies (instituting comprehensive anti-racist and Diversity, Equity and Inclusion policies, monitoring and feedback systems; workforce equity), at the top two levels of the socioecological model (organizational/policy and systems/providers/staff), to in turn impact individual-level out-comes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRAncenDS
Description: The HP+ curriculum includes total-site training and co-facilitation via participatory modules. To transform clinic culture, a multi-level approach that includes the whole facility and reaches all parties is required. The intervention aims to modify top-down mechanisms of influence. TRAnscenDS is modeled on these principles and supports the development of multiple SRD-reduction strategies (instituting comprehensive anti-racist and Diversity, Equity and Inclusion policies, monitoring and feedback systems; workforce equity), at the top two levels of the socioecological model (organizational/policy and systems/providers/staff), to in turn impact individual-level out-comes.
Study: NCT06474819

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker implant
Description: All patients in the study will have a clear indication for a permanent pacemaker. The type of device (single or dual chamber) will be chosen as per clinical practice. The only difference between the two groups of the study will be the position of the ventricular lead.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacemaker implant
Description: All patients in the study will have a clear indication for a permanent pacemaker. The type of device (single or dual chamber) will be chosen as per clinical practice. The only difference between the two groups of the study will be the position of the ventricular lead.
Study: NCT05129228

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT-guided saphenous vein CABG
Description: OCT examination of harvested saphenous vein conduits will indicate pathology. Under the surgeon's discretion the conduit segments with pathology will not be grafted.
Study: NCT01354184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRD007
Study: NCT05051163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone Sodium
Description: 7 days of once daily dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin
Description: 7 days of 6 hourly dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin
Description: 7 days of once daily dosing
Study: NCT01354184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRD007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRD007

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CRD007 matching placebo
Study: NCT05286320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib/Pembrolizumab plus SBRT combinations
Description: Five-fraction SBRT (week 4-week 5) to PVTT and connected HCC tumor in 2 weeks Lenvatinib 12/8 mg/day for 96 weeks (no lenvatinib from 7 day before SBRT to 7 days after SBRT) Pembrolizumab 200 mg q 3 week x 32 cycles
Study: NCT06317974

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding education based on the Health Belief model
Description: Training was given face to face with the participant, lasting approximately 40 minutes. One week after the training presentation, three short messages about the training were sent to the couples (both the pregnant woman and her partner) every other day. Two weeks after the training was given, a phone call was made for feedback. Post-test data were taken four weeks later.